Randomized Trialhigh evidence
Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial.
JAMA·April 28, 2026·PMID 41903215
Why it mattersThis is the first large trial to show that intensive LDL-C lowering with a PCSK9 inhibitor can prevent first cardiovascular events in high-risk diabetic patients without established atherosclerotic disease, expanding the potential role of evolocumab beyond secondary prevention.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled